Join PER® September 15th for the New York Advanced Practice Collaborative Meeting! Directed toward NP/PAs, this meeting blends presentations on cutting-edge information with panel discussions to enhance learning.

Peripheral Neuropathy

Monday, July 21, 2014
One of the most debilitating side effects of cancer treatment is the development of chemotherapy-induced peripheral neuropathy (CIPN). As clinicians, we are all too familiar with how patients’ lives are affected. Patients report struggling with everyday activities, such as dressing, eating, and working.

The American Society of Clinical Oncology (ASCO) convened a panel of experts to identify best practices for preventing and managing CIPN, and the panel reviewed 42 studies published in the past 23 years. Unfortunately, none of the studies provided definitive guidance, and most had an insufficient sample size, lost patients to follow-up, and/or had inconclusive findings. The expert panel compiled a list of 11 established agents that should not be offered to prevent CIPN, including anticonvulsants, antidepressants, vitamins, minerals, supplements and other chemo-protectants. No agents were recommended. One trial involving venlafaxine was inconclusive and merits further investigation. The panel also reviewed treatment for patients experiencing CIPN and supported a moderate recommendation of duloxetine, which was effective in cancer-related trials and is used for treatment of diabetic peripheral neuropathy. The panel made no recommendation or endorsement of four other agents shown to be beneficial in small or unpublished studies: acetyl-l-carnitine, tricyclic antidepressants (TCAs); gabapentin or pregabalin; and a compounded gel consisting of baclofen, amitriptyline HCL and ketamine.

Probably the biggest take-home message here is that as clinicians, we need to teach our patients about CIPN and assess for CIPN. From the literature review conducted by the ASCO expert panel, it appears that promptly recognizing CIPN and when indicated, modifying the patient’s chemotherapy regimen, may be the best action for reducing CIPN progression.

Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. JCO 32(18):1941-1967.  

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
Blog Info
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN is an oncology nursing consultant and editor-in-chief of Oncology Nursing News.
Author Bio
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN, is the Editor-in-Chief for OncLive Nursing. She is an oncology nursing consultant and adjunct assistant professor of nursing at Louisiana State Health Sciences Center in New Orleans, LA. She provides continuing nursing education to nurses across the Unites States, is active in several professional nursing organizations, and is intrigued by the many ways nurses use technology to communicate.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.